Zydus Lifesciences gets USFDA EIR for formulation manufacturing facility at SEZ 2, Ahmedabad
Ahmedabad: Zydus Lifesciences has announced that the company has received the Establishment Investigation Report (EIR) report from the United States Food and Drug Administration (USFDA) for the inspection conducted at the formulation manufacturing facility named ‘SEZ 2’ located at Pharmez, Ahmedabad from 3rd to 7th July, 2023.
This was a Pre-Approval Inspection (PAI) and had concluded with NIL observations.
Read also: Zydus Lifesciences concludes USFDA inspection at Ahmedabad facility with nil observations
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian Pharmaceutical company headquartered in Ahmedabad. The Company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals. It is primarily engaged in the manufacture of generic drugs.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd